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Transforming growth factor-b isoforms and glomerular injury ing molecules with important roles in embryogenesis and
in nephrotoxic nephritis. development, immunity and inflammation, and wound
Background. Transforming growth factor-b has three main healing and scarring [1]. Mammals express three iso-isoforms (TGF-b1, TGF-b2, and TGF-b3) that have distinct
forms (TGF-b1, TGF-b2, and TGF-b3) that are synthe-but overlapping functions in immunity, inflammation, and tis-
sized in the latent form and that are activated by proteo-sue repair. TGF-b1 has been implicated in progressive renal
scarring, but the roles of TGF-b2 and TGF-b3 are less clear. lytic cleavage from the latency-associated protein [2].
The purpose of this study was to characterize the expression The isoforms have very different promoter regions [3],
of all three isoforms in nephrotoxic nephritis (NTN) in rats and show distinct patterns of spatial and temporal expres-and to determine the effect of TGF-b3 infusions on injury
sion during embryogenesis and in inflammation [4, 5].because of its reported combined anti-inflammatory and anti-
TGF-b1 is detectable in plasma and functions as a hor-fibrotic effects.
Methods. TGF-b1, TGF-b2, and TGF-b3 expression was an- mone, whereas TGF-b2 and TGF-b3 have purely local
alyzed by immunohistochemistry and RNase protection assays. effects [6]. They bind to the same receptor but have
TGF-b3 was administered by osmotic minipumps at 2 mg/day, different biological functions. For example, TGF-b1a dose shown to alter glomerular macrophage function in vivo.
knockout mice develop widespread systemic inflamma-Injury was assessed morphologically and functionally.
tion and autoantibody formation [7]. TGF-b3 knockoutsResults. The three TGF-b isoforms showed a different distri-
bution in normal rats and after the induction of nephritis. have developmental abnormalities of palatogenesis and
TGF-b1 was only detected in glomeruli of the most severely pulmonary maturation [8], and TGF-b2 knockout mice
nephritic rats. TGF-b2 was found in glomerular neutrophils,
have numerous other developmental abnormalities [9].whereas damaged podocytes expressed TGF-b3. Infusions of
Thus, despite having very similar effects on cells culturedTGF-b3 did not reduce proteinuria over seven days after the
induction of nephritis. They did, however, have a profound in vitro, TGF-b1, TGF-b2, and TGF-b3 are not function-
effect on glomerular macrophage number (7.76 6 4.1 in treated ally redundant in vivo during embryogenesis or postna-
rats vs. 14.4 6 4.7 in controls, P , 0.02). The numbers of tally. TGF-b3 may even be a physiological antagonist ofclass II-positive macrophages were similar in the two groups,
the profibrotic properties of TGF-b1 and TGF-b2 onwhereas class II-negative macrophages infiltrating glomeruli
scar formation in wounds [10].were significantly decreased (4.06 6 3.1 vs. 9.1 6 4.4, P , 0.02).
TGF-b did not influence the amount of glomerular matrix. Transforming growth factor-b1 regulates healing of
Conclusions. TGF-b isoforms have different expressions cutaneous wounds [1], and there is indirect evidence that
and presumptively different roles in NTN. The infusion of
it also causes scarring in viscera, including the kidney.pharmacological doses of TGF-b3 has profound effects on mac-
Glomerular TGF-b1 expression is increased in clinicalrophages infiltrating nephritic glomeruli and reveals marked
heterogeneity of infiltrating macrophages. [11] and experimentally induced [12] nephritis, and the
overexpression of TGF-b1 in rat glomeruli by in vivo
gene transfer is associated with the accumulation of ex-
The transforming growth factor-b (TGF-b) family of tracellular matrix [13]. Furthermore, therapeutic strate-
proteins is a highly conserved set of intercellular signal- gies to block TGF-b1 in the Thy 1.1 experimental model
of nephritis attenuate the increase in matrix synthesis
[14, 15]. TGF-b2 and TGF-b3 are more abundant inKey words: nephrotoxic nephritis, macrophage, inflammation, tissue
repair, progressive renal disease. Heyman nephritis, a rat model of membranous nephrop-
athy [16], and are up-regulated in obstructive nephropa-Received for publication September 16, 1999
thy in rats in which the abundance of TGF-b2 is increasedand in revised form December 17, 1999
Accepted for publication January 18, 2000 in the acute stages and TGF-b1 and TGF-b3 in the
chronic stages of the disease [6].Ó 2000 by the International Society of Nephrology
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Transforming growth factor-b2 and TGF-b3 have not Morphology
been investigated in acute inflammatory models of ne- The kidneys were removed immediately after death,
phritis, but could be important because of their influence and portions of tissue were snap frozen or fixed in forma-
on immune and inflammatory responses [17]. TGF-b lin or methyl Carnoy’s and processed through to wax.
represses B-cell proliferation and immunoglobulin secre- Wax sections were cut at 5 mm for hematoxylin and eosin
tion. It also decreases mitogenesis and cytokine produc- and methenamine silver stain. Tissue for electron micros-
tion by T lymphocytes and inhibits natural killer cell copy was fixed in 4% formaldehyde/1% gluteraldehyde
function [1, 17]. Under some conditions, TGF-b inhibits in phosphate buffer, followed by standard processing to
leukocyte adhesion to the endothelium and prevents the epoxy resin. Glomeruli were assessed morphometrically
activation of inflammatory macrophages, thus decreasing using a Leica QMC imaging system. Glomerular area
their capacity to release proinflammatory cytokines and was calculated from the mean area of 20 glomerular tufts
toxic oxygen radicals [1, 17]. TGF-b also has immunosup- within a single hematoxylin and eosin-stained section,
pressive and anti-inflammatory effects in vivo and de- and the number of cells within the same glomeruli was
creases injury in a variety of rodent models of autoimmune estimated from the nuclear counts. The extent of glomer-
disease, including inflammation in adjuvant arthritis, ex- ular matrix was scored semiquantitatively based on a
perimental allergic encephalomyelitis, insulitis in NOD method described by Floege et al in which 20 consecutive
mice, and glomerulonephritis in lupus-prone strains of cortical glomeruli were assessed in coded silver stained
mice [18]. It is notable that treatment with TGF-b1 in sections by an experienced renal pathologist [22]. Mean
these settings does not increase scarring. There is a clear values per biopsy were calculated based on the extent,
need to define the role (or roles) of TGF-b isoforms not the intensity of mesangial matrix stained by the me-
in acute glomerular inflammation, especially because of thenamine silver method: 0 5 diffuse, minor or absent
their potential as targets for therapeutic intervention. mesangial matrix staining; 1 5 diffuse, mesangial matrix
The purpose of this study was to characterize the ex- staining involving up to 25% of the glomerular tuft; 2 5
pression of the three isoforms during the first 14 days of 25 to 50% of the glomerular tuft demonstrating staining;
an acute inflammatory model of nephritis—accelerated 3 5 50 to 75% of the glomerular tuft stained; 4 5 .75%
nephrotoxic nephritis (NTN) in rats—and second to of the glomerular tuft stained.
determine whether injury was influenced by infusing
ImmunohistochemistryTGF-b3. TGF-b3 was chosen for the infusion studies
because it shares the anti-inflammatory properties with The expression of TGF-b1, TGF-b2, and TGF-b3 was
the other two isoforms, but may antagonize their effects assessed by indirect immunoperoxidase staining of methyl
on scarring. The results demonstrate different expression Carnoy’s-fixed sections using specific rabbit antihuman
of the isoforms in inflamed glomeruli. Infusions of polyclonal antibodies, which cross-react with rat tissue
TGF-b3 decrease glomerular hypercellularity predomi- (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Sec-
nantly due to a population of non–class II-expressing tions were dewaxed, and endogenous peroxidase activity
macrophages. Despite this, there was no effect on pro- was quenched by incubating the slides in Tris-buffered
teinuria. saline (TBS)/1% hydrogen peroxide for 10 minutes and
was blocked with 5% normal goat serum. Endogenous
biotin was blocked with an avidin/biotin blocking kitMETHODS
(Vector Laboratories Inc., Burlingame, CA, USA), and
Accelerated nephrotoxic nephritis sections were incubated overnight at 48C with anti–TGF-
Nephrotoxic serum was prepared from sheep immu- b1, anti–TGF-b2, or anti–TGF-b3 antibodies [1:200
nized with rat glomerular basement membrane (GBM) dilution in TBS/0.1% bovine serum albumin (BSA)].
as described previously [19]. Accelerated NTN was in- Bound antibody was detected using indirect immunoper-
duced in Sprague-Dawley rats by a single intravenous oxidase staining with diaminobenzidine tetrahydrochlo-
injection of nephrotoxic serum seven days after the rats ride (0.05%) as a substrate. There was no immunostain-
had been immunized with 1 mg normal sheep IgG. ing in control sections in which primary antibody was
Groups of rats were killed at 1 and 4 hours after the omitted or when primary antibody was substituted by
induction of nephritis and at 1, 2, 4, 7, and 14 days later. preimmune rabbit serum. In addition, preabsorbing the
The severity of nephritis was assessed both functionally antiserum with TGF-b1–, TGF-b2–, or TGF-b3–specific
and morphologically using our standard methods [20]. peptides abolished binding to tissue sections. TGF-b ex-
Albuminuria was measured in 17-hour urine collections pression was graded semiquantitatively: 0 5 background
by rocket immunoelectrophoresis [21], immediately be- staining, 1 5 mild staining, 2 5 moderate staining, and
fore induction of nephritis, and at standard time points 3 5 strong staining. The mean score values were calcu-
lated for each biopsy.throughout the experiments.
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Macrophages were identified using a mouse antirat Two concentrations of RNA (1 and 3 mg) were used
with each probe to confirm it was in excess. RNA wasantibody (ED1, 1:50; Serotec, Oxford, UK), and macro-
hybridized overnight at 458C with the 32P-labeled probephage activation was determined by major histocompati-
and digested with RNase. The RNA/RNA hybrids werebility complex (MHC) class II expression using mouse
precipitated, dissolved in formamide buffer, and sepa-antirat Ia, Ox-6 clone, 1:50 (Serotec). Neutrophils were
rated on a 6% polyacrylamide 7 mol/L urea gel. Changesstained with the monoclonal antibody RP-3 or MCA
in the intensity of RNA were confirmed by densitometry.149A (Serotec) and were also counted in chloroesterase-
stained, formalin-fixed sections [19]. Glomerular macro-
Administration of recombinant TGF-b3
phages, neutrophils, and class II-positive cells were ex-
Recombinant TGF-b3 was provided by Dr. David Coxpressed both as the mean cell number per glomerulus
(Ciba Geigy, Basel, Switzerland). It was administeredand per glomerular area (GA; 10,000 mm2). Some sec-
continuously using Alzet model 2001 osmotic minipumpstions were doubly stained first with TGF-b antisera and
(Alzet, Palo Alto, CA, USA) with a volume capacity ofthen with ED-1 or RP-3. Deposition of sheep and rat
200 mL and a delivery rate of 1 mL/h for one week.IgG on the GBM was quantitated by direct immunofluo-
The minipumps were filled with TGF-b3 in one of tworescence on frozen sections.
concentrations, which were calculated to deliver doses
equivalent to 0.5 or 2 mg TGF-b3 per day or with normalIsolation of rat neutrophils
saline as a control. The doses were chosen on the basis
Neutrophils were obtained from Sprague-Dawley rats of previous TGF-b1 dose defining experiments described
after an intraperitoneal injection of 4% thioglycollate. by Terrell et al [23]. The pumps were implanted subcuta-
Four hours later, the peritoneum was lavaged with PBS, neously by a small incision on the back of the rats under
and the neutrophils were recovered by centrifugation. light anesthesia, either in control rats or 24 hours before
Peripheral blood neutrophils were purified from whole the induction of nephritis.
blood by centrifugation through Hypaque-Ficoll at 500 3 g
Isolation of glomerular macrophages andfor 30 minutes. The granulocyte layer was collected and
b-glucuronidase stainingwashed three times with PBS before plating by cytocen-
trifugation; their purity was assessed using Geimsa stain. Glomeruli were isolated using a standard sieving tech-
nique and isolated glomeruli enzymatically digested to a
RNase protection assays single cell suspension using trypsin, collagenase, DNase,
Preparation of radiolabeled probes. TGF-b1, TGF-b2, and ethylenediaminetetraacetic acid (EDTA) as de-
scribed [24]. b-glucuronidase was visualized by an enzy-and TGF-b3 antisense RNA probes were prepared from
matic staining method in which b-glucuronidase cata-plasmids pmTGF-b1a, pmTGF-b2-9A, and pmTGF-b3-
lyzed the reaction of a-naphtol AS-BI b-D-glucuronide11c, which were generously provided by Dr. H.L. Moses
into the red soluble-chromogenic naphtol AS-BI-HPR(Vanderbilt University, Nashville, TN, USA). The glycer-
complex [25]. Cytospin preparations of macrophagesaldehyde-3-phosphate dehydrogenase (GAPDH) RNA
harvested from glomeruli were fixed in a glutaraldehyde-probe was prepared from a DNA template included in
acetone solution, and the sections were air dried andan Amersham ribonuclease protection kit. Plasmid DNA
stained with b-glucuronidase staining solution and coun-was linearized by digestion with Bgl I, Bgl II, and Sac I
terstained in methylene blue. Slides were coded andfor TGF-b1, TGF-b2, and TGF-b3, respectively. RNase-
scored according to our standard system [25] using thefree DNase I was added and incubated for 20 minutes
following scale: 0 5 no staining; 1 5 equivocal positiveat 378C, and RNA-radiolabeled probes were prepared
staining; 2 5 weak positive staining; 3 5 moderate posi-using a Boehringer SP6/T7 transcription kit. Probes were
tive staining; and 4 5 strong positive staining. The scorepurified by gel filtration on a Sephadex G50 column. The
represents an overall change in the density of staining.mixture was extracted with phenol chloroform (1:1), and
after ethanol precipitation and centrifugation, the RNA Statistical methods
pellet was dried and resuspended in diethyl pyrocarbonate- All data presented are mean values 6 SD. Statistical
treated water. The total length of the purified probes analyses were performed by Wilcoxon rank sum test or
was longer than the protected fragment because of the in the case of correlations by Spearman’s rank correla-
presence of polylinker site nucleotides; this allowed a clear tion test. A value of P , 0.05 was defined as statistically
separation of the undigested probe and the protected significant.
fragments, which were 397, 447, 331, and 100 bp for
TGF-b1, TGF-b2, TGF-b3, and GAPDH, respectively.
RESULTSRNA isolation and RNase protection assay. Glomeruli
Severity of nephritisfrom control and diseased animals were isolated [19] and
RNA extracted six days after the induction of nephritis, All rats injected with nephrotoxic antibodies devel-
oped diffuse proliferative glomerulonephritis with heavyusing guanidine thiocyanate and homogenization [19].
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albuminuria within 24 hours, which was sustained until Transforming growth factor-b3 was detectable in glo-
meruli of normal rats, but was much more strongly ex-the end of the experiment at day 14. Neutrophils infil-
trated glomeruli one hour after the induction of nephri- pressed in tubules, especially in the brush border of prox-
imal tubules of the outer cortex of the kidney (Fig. 1E).tis, and their number increased to a maximum at four
hours. The glomeruli were also infiltrated with macro- There was no change in this staining in the first few days
after the induction of nephritis, but from seven daysphages in which the number peaked between days 4 and
7. The mean glomerular cell counts increased signifi- onward, the podocytes were strongly positive (Fig. 1F).
TGF-b3 expression coincided with the development ofcantly from 44 6 7 in normal rats to 87 6 12 (P , 0.05)
at day 14 postnephritis. The GA increased from 8113 6 severe podocyte injury seen by electron microscopy,
which also demonstrated normal morphology at day 2.1512 to 12519 6 992 (P , 0.05). The glomerular matrix
score also increased from a mean of 1.5 6 0.2 in normal TGF-b3 immunostaining in podocytes increased over two-
fold by day 7 and was sustained until at least day 14 (Fig.rats to 2.75 6 0.5 on day 14 (P , 0.05).
4). A subpopulation of macrophages in dermal wounds
Distribution of TGF-b isoforms in synthesized TGF-b3 [26], but none of the TGF-b3–
nephrotoxic nephritis positive cells were stained with the macrophage-specific
antibody ED-1 (Fig. 5). Around 5% of glomerular neu-Transforming growth factor-b1, TGF-b2, and TGF-b3
were differentially expressed in both normal (Fig. 1 A, trophils were positive for TGF-b3, but the intensity of
staining was weak and considerably less than thoseC, and E) and nephritic (Fig. 1 B, D, and E) rat kidneys.
In normal rats, TGF-b1 was expressed strongly in affer- stained for TGF-b2. RNase protection assays confirmed
an increase in TGF-b3 mRNA (Fig. 2c).ent and efferent arterioles and was localized in the cyto-
plasm of smooth muscle cells rather than to endothelium
Expression of TGF-b by neutrophils(Fig. 1A). Neither smooth muscle cells nor endothelium
of larger arteries stained for TGF-b1. The glomeruli were Neutrophils have previously been reported to produce
TGF-b1 [27], but not TGF-b2 or TGF-b3. We thereforealso negative but proximal convoluted tubules were
weakly positive. In seven of the nine nephritic rats, examined rat neutrophils from two sources: nonactivated
peripheral blood neutrophils and activated peritonealTGF-b1 staining was indistinguishable from normal
throughout the time course examined. However, glomer- neutrophils, harvested four hours after injection with
thioglycollate. Neutrophils from both sources staineduli from the remaining two rats had strong diffuse
TGF-b1 staining when they were killed seven days after strongly for TGF-b2 and TGF-b3, but staining for
TGF-b1 was indistinguishable from background (datathe induction of nephritis (Fig. 1B). These rats had the
most severe nephritis assessed both histologically and not shown), which emphasizes the lack of TGF-b1 syn-
thesis.by albumin excretion, with mean GAs of 15,600 and
13,900 mm2 compared with an average of 9184 mm2 for
Effect of TGF-b3 infusion in normal rat kidneynephritic rats as a whole. There was a small increase in
glomerular TGF-b1 mRNA in one of three of the rats, We next determined whether infusions of TGF-b3 in-
fluenced inflammation or matrix synthesis in NTN. Initialas assessed by RNA protection assays (Fig. 2a).
The expression of TGF-b2 was very different, with studies were performed to find a suitable dose. The rats
infused for seven days with 0.5 mg/day or 2 mg/daystrong staining of the basolateral aspect of distal tubules
and weak staining of proximal tubules of normal rats TGF-b3 remained healthy and showed no significant dif-
ference in weight compared with saline-infused controls.(Fig. 1C). TGF-b2 was not found in arterioles or capillar-
ies of normal glomeruli, but between two and four cells None developed albuminuria, and those infused with 0.5
mg/day had normal renal morphology at autopsy. Byper glomerular section stained strongly for TGF-b2
within an hour of induction of nephritis. This pattern contrast, rats infused with 2 mg/day of TGF-b3 had sig-
nificantly more glomerular macrophages with 1.6 6 0.02persisted for 24 hours (Fig. 1D). The rapidity of appear-
ance suggested that infiltrating cells rather than intrinsic macrophages/glomerulus compared with 0.5 6 0.01 for
the controls and 0.6 6 0.01 for the group infused withglomerular cells were responsible. This was supported
by the observation that their numbers correlated with 0.5 mg/day. Rats treated with 2 mg/day TGF-b3 also had
more intense proximal tubular staining for TGF-b3. Un-those of neutrophils (Fig. 3). The positive cells had
multilobed nuclei and stained with an antigranulocyte committed rat bone marrow-derived macrophages and
macrophages purified from normal rat glomeruli developmarker, MCA 149A, which confirmed they were neutro-
phils (data not shown). Approximately 80% of glomeru- intense expression of the lysosomal enzyme b-glucuroni-
dase when treated with TGF-b [25], and so b-glucuroni-lar neutrophils stained positively for TGF-b2, and the
proportion did not change during the course of nephritis dase expression was used as a marker for the in vivo
effect of TGF-b on glomerular macrophages. Glomeru-(Fig. 3). TGF-b2 mRNA increased at two days, and the
increase was sustained for at least six days (Fig. 2b). lar macrophages from the TGF-b3–infused rats expressed
Fig. 1. Immunostaining for transforming growth factor-b (TGF-b) isoforms. In the normal rat glomerulus, TGF-b1 staining was restricted to
glomerular arterioles (A), with increased staining in the most severe cases of nephritis (2 out of 9 rats) at day 7 (B). TGF-b2 in the normal rat
glomerulus showed strong staining at the basolateral surface of distal tubules and weak stain in the proximal tubules (C). Neutrophils infiltrating
the glomerulus showed strong positive staining in diseased animals 1, 4, and 24 hours after induction of nephritis (D). Immunostaining for TGF-b3
in normal kidney was strongly positive in the brush border of proximal tubules with little glomerular stain (E). There was a marked up-regulation
of TGF-b3 in glomerular epithelial cells seven days after the induction of nephritis (F ). Magnifications are 3400 for A–C, E, F, and 31000 for
D and insert F.
Fig. 5. Immunostaining for TGF-b3 and ED-1. Double staining in rat
glomeruli for TGF-b3 (brown) and ED-1 representing macrophages
(red), demonstrating that it was podocytes and not macrophages that
stained positively for TGF-b3 (3400).
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Fig. 2. RNase protection assays for TGF-b
isoforms from glomerular RNA of control and
nephritic rats. RNase protection assays for
TGF-b1 (a), TGF-b2 (b), TGF-b3 (c), and
GAPDH (d) were performed using RNA iso-
lated from glomeruli from control (C) and
diseased (D) rats six days after the induction
of nephritis. There was a small increase in
glomerular mRNA for TGF-b1 in one out of
three nephritic rats (a); TGF-b2 and TGF-b3
mRNA showed a significant up-regulation in
all nephritic rats examined.
significantly greater amounts (P , 0.05) of b glucuroni- with albuminuria that ranged from 8.6 to 204 mg/20 h
on day 2 and 9.2 to 790 mg/20 h on day 7. The glomerulidase than controls (mean score 2.2 6 0.2 for the 0.5 mg/
day group, 2.9 6 0.3 for the 2 mg/day group, and 1.6 6 were enlarged and had increased matrix deposition.
There was no difference in glomerular surface area,0.3 for controls). Thus, infusions of both doses of TGF-b3
affected the properties of glomerular macrophages in glomerular cell counts, or matrix area in TGF-b3–treated
and –untreated nephritic controls killed at day 2 (Tablevivo.
1). The number of macrophages infiltrating the glomeruli
Effect of continuous infusion of TGF-b3 2 mg/day on was also similar, as was the number of glomerular cells
glomerular injury in NTN expressing MHC class II; macrophages form the majority
of MHC class II-positive cells in the rat glomerulus [28].Next, we assessed the effect of TGF-b3 on injury in
TGF-b3–infused rats and controls also had similar in-NTN by comparing the severity of injury in a group of
creases in glomerular surface area and matrix accumula-11 rats infused with 2 mg/day TGF-b3 per day to that of
tion at day 7, but by this time, there was a markedan equal number of saline-treated controls. Three rats
difference in the degree of glomerular cellularity (Tablefrom each group were killed two days after the induction
1). Treated rats had significantly fewer glomerular cellsof nephritis to assess the effect of treatment on early
compared with controls, principally because of a de-injury, and the remaining eight were killed at the end of
the experiment on day 7. All the rats developed nephritis crease in the number of infiltrating macrophages. De-
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Table 1. Evaluation of glomerular injury in saline infused and
transforming factor-b3 (TGF-b3) infused nephritic rats
Saline infused TGF-b3 infused
Day 2
Total glomerular cells 53.266.1 41.164.0
Total glomerular cells/GA 65.466.2 49.165.1
Glomerular area lm2 81566284 82676712
Matrix score 2.360.03 2.160.1
Macrophages/glomerulus 1.9261.1 2.461.4
Macrophages/GA 2.160.8 2.861.3
Class II positive cells/glomerulus 0.7660.1 0.7960.2
Day 7
Total glomerular cells 81.168.1 67.268.0a
Total glomerular cells/GA 89.268.2 72.262.1a
Glomerular area lm2 91706915 92006985
Matrix score 2.460.2 2.460.3
Macrophages/glomerulus 14.464.6 7.764.1b
Macrophages/GA 14.264.7 5.762.9b
Class II positive cells/glomerulus 5.362.6 3.761.7
Class II negative cells/glomerulus 9.164.4 4.063.6b
Results are mean values 6 SD. At day 7 the mean number of glomerular
cells was decreased in TGF-b3 infused ratsa (P , 0.05), as was the number of
macrophages/glomerulus and class II-negative cellsb (P , 0.02). The range forFig. 3. Neutrophil and TGF-b2–positive cell counts in nephrotoxic
glomerular cell counts, glomerular area (GA), and matrix score in normal ratsnephritis (NTN). There was a strong correlation between TGF-b2–
is 44 6 7, 8113 6 1512, and 1.5 6 0.2, respectively.positive cells (s) and neutrophils (j) at all time points examined, with
around 77% of neutrophils staining positively for TGF-b2.
lus. The experiments do not distinguish between de-
creased influx, increased removal, or altered activation
of macrophages.
Treatment with TGF-b3 did not significantly reduce
albuminuria despite the marked reduction in glomerular
macrophages (Table 2). This is surprising because injury
in accelerated NTN is macrophage dependent and glo-
merular macrophage numbers have been reported to
correlate with albuminuria [29]. However, this correla-
tion was observed four days after the induction of nephri-
tis. This is consistent with our data on day 2 but contrasts
with the results at day 7 (Fig. 6A). More detailed exami-
nation of the macrophages showed that the number of
class II-positive macrophages correlated with albumin-
uria in treated and control nephritic rats and at both
days (Fig. 6B). By contrast, there was no correlation
between class II-negative macrophages and injury. Inter-
estingly, there was a significant correlation between the
total glomerular macrophages, as well as class II-positiveFig. 4. Immunostaining score for TGF-b3 in control rats (C) and rats
1 and 4 hours and 1, 2, 4, 7, and 14 days after the induction of NTN. macrophages and albuminuria in the TGF-b3–treated
Twenty glomerular profiles from each renal biopsy were evaluated. group at day 7 (Fig. 6 C, D) because of the reduction ofThere was a significant increase in TGF-b3 at day 7, and this was
class II-negative macrophages at that time. Thus, TGF-b3sustained at day 14. *P , 0.001 vs. control rats.
infusion has a selective effect in removing a subset of
class II-negative macrophages that are not involved in
injury.
spite the reduction in total macrophage numbers, there
was little difference in the number of class II–positive
DISCUSSION(presumably activated) macrophages in TGF-b3–treated
rats (Table 1). The expression of b-glucuronidase by There is compelling evidence for the involvement of
TGF-b in progressive renal disease, and this makes it anisolated glomerular macrophages from TGF-b3–treated
rats was not increased and was not different from saline- obvious target for therapeutic intervention. However,
the TGF-b system has now been shown to be much moretreated rats. Thus, infusion of TGF-b3 selectively re-
duces class II-negative macrophages within the glomeru- complex than originally thought, which makes it difficult
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Table 2. Effect of TGF-b3 infusion on albuminuria in the of them contained TGF-b2. None of the neutrophils
accelerated phase of nephrotoxic nephritis
stained for TGF-b1 and only about 5% were positive
Saline infused TGF-b3 infused for TGF-b3. Glomerular neutrophils have not previously
albuminuria mg/20 h been identified as sources of TGF-b, but in vitro studies
with nonspecific antibodies have suggested that they syn-day 1 64615 51612
day 2 61616 40611 thesize TGF-b1 [27]. We therefore purified peripheral
day 4 85626 60616 blood neutrophils as well as elicited peritoneal neutro-
day 7 173630 171626
phils to ascertain which TGF-b isoforms were expressed.
There was no significant effect on albumin concentrations in TGF-b3 infused
As with glomerular neutrophils, both types stained forrats as compared with saline infused controls. Urinary albumin was measured
by rocket immunoelectrophoresis and was expressed as mg/20 h. The infusion TGF-b2 and TGF-b3 but not for TGF-1. Therefore, neu-
of TGF-b3 in non-nephritic rats did not cause any albuminuria.
trophils can deliver TGF-b2 to the inflamed glomerulus
where it could have profound consequences, as has been
described in other settings [32, 33]. We found no increase
in TGF-b2 staining in podocytes in NTN, which contraststo predict the consequences of a given intervention.
Three properties in particular underscore the need to with results in experimental membranous nephropathy
[16]; this could reflect differences in the severity or naturere-evaluate TGF-b in renal disease: (1) the distinct role
of the different isoforms, with the suggestion that TGF- of the epithelial injury in the two models.
Transforming growth factor-b3 was strongly and spe-b3 antagonizes the profibrotic effects of b1 and b2 [10];
(2) the immunosuppressive and anti-inflammatory ef- cifically increased in a glomerular epithelial cell distribu-
tion at day 7, a time point in which podocyte injury wasfects of all three isoforms could offset TGF-b’s profi-
brotic effects; (3) cellular responses to TGF-b are criti- most obvious by electron microscopy. This is consistent
with studies by Shankland et al in Heyman nephritiscally dependent on the context in which cells they occur,
and can be radically altered by the presence of other [16]. The functional consequences of podocyte TGF-b3
expression are not clear, but in other settings, it inhibitscytokines. The dual purposes of the experiments re-
ported here were to relate the expression of TGF-b iso- epithelial cell proliferation [34]. TGF-b3 is expressed in
alveolar epithelium after completion of wound healingforms to injury during the acute phase of NTN and to
ascertain whether infusions of TGF-b3 would influence and in the reparative phase of experimental lung disease,
suggesting a general role in restoring normal functionthe intensity of glomerular inflammation.
Glomerular expression of TGF-b1, TGF-b2, and TGF- after injury [35]. During wound healing, TGF-b3 is up-
regulated in the migrating epidermis of full thicknessb3 was very different in normal animals and in those
with nephritis. Perhaps the most surprising observation skin wounds [36], where it regulates keratinocyte differ-
entiation and epidermal repair processes. It will be inter-was the absence of detectable TGF-b1 in the glomeruli
of most of the rats, even though they developed obvious esting to determine whether the up-regulation of TGF-b3
in podocytes has a similar role in NTN.nephritis with marked leukocyte infiltration and heavy
proteinuria. TGF-b1 expression was also minimal in Transforming growth factor-b3 was selected for these
intervention studies because of the immunosuppressiveHeyman nephritis [16] and in our model of Thy 1.1 mes-
angioproliferative nephritis (abstract; Minto AW et al, properties that it shares with the other isoforms, which
are complemented by its antifibrotic effects, at least whenJ Am Soc Nephrol 18: 503, 1997) in which there was no
glomerular TGF-b1, but TGF-b2 and TGF-b3 were up- applied locally to skin wounds [10]. Choosing appro-
priate doses of cytokines for in vivo studies is very uncer-regulated in disease. Glomerular TGF-b1 was detected
in only the two most severely nephritic rats, and it was tain, but it was clear from the experiments in normal rats
that 2 mg/day influenced glomerular macrophages in vivo:diffusely present rather than in specific cells. An increase
in glomerular staining has been similarly reported in It increased the numbers of glomerular macrophages and
altered the amount of b-glucuronidase they expressed.experimental diabetes mellitus [30] and in a Thy 1.1
model of nephritis [12], although these groups also found Despite this, infusions of TGF-b3 did not reduce albu-
minuria. These results need to be put into context ofglomerular staining, to a lesser degree, in nondiseased
animals. The diffuse glomerular TGF-b1 staining seen other studies in which cytokines and their inhibitors have
been infused into rats with NTN [37–39]. Treatment within our experiments is probably due to circulating TGF-b1
or TGF-b1 released from platelets [31], bound to glomer- interleukin-4 (IL-4) and IL-6 has both been reported to
reduce glomerular injury and reduce macrophage infil-ular matrix structures. This pattern of glomerular expres-
sion contrasts with those of TGF-b2 and -b3. tration [29, 40]. However, these appear to affect macro-
phage activation to a greater extent than macrophageTransforming growth factor-b2 was detected in glo-
meruli within an hour of induction of nephritis excluding numbers. Chadban et al reported that IL-10 treatment
neither reduced nor increased albuminuria, even thoughsynthesis by intrinsic glomerular cells. In fact, infiltrating
neutrophils were the only positive cells, and over 80% it promoted glomerular macrophage proliferation and
Wilson et al: TGF-b isoforms and glomerular injury in NTN2442
Fig. 6. Relationship between the number of glomerular macrophages and albuminuria on day 7 in saline and TGF-b3–infused nephritic rats. The
relationship between the mean number of macrophages per glomerulus and albuminuria (mg/20 h) in saline (A; r 5 0.357, P 5 0.53) and TGF-b3
(B; r 5 0.883, P 5 0.005)–infused rats was assessed; only TGF-b3–infused rats showed a significant correlation. However, when the relationship
between the mean number of class II-positive macrophages and albuminuria was determined, both saline-infused (C; r 5 0.667, P 5 0.049) and
TGF-b3–infused (D; r 5 0.714, P 5 0.374) rats showed a significant correlation.
increased their number [41]. Our results with TGF-b3 phages in the first few days after induction of NTN ex-
press class II and generate large amounts of nitric oxide.show that total macrophage numbers decreased with lit-
tle change in the numbers of class II-positive cells. Thus, These properties can be reproduced in vitro by exposure
of uncommitted bone marrow-derived macrophages toall of these studies emphasize the heterogeneity of mac-
rophages within nephritic glomeruli and suggest that interferon-g (IFN-g) followed by tumor necrosis fac-
tor-a. The exposure of bone marrow-derived macro-some macrophages, including those that are class II posi-
tive, cause injury while others have less well-defined phages to IL-4 at the same time as IFN-g reduces nitric
oxide generation, whereas treatment with TGF-b doesroles.
The results can also be related to the effects of cyto- not and only reduces nitric oxide generation if given
before exposure to IFN-g [25]. IL-10 has no effect onkines in macrophages in vitro, especially the contrasting
effects of TGF-b3 infusions on b-glucuronidase expres- nitric oxide generation in this system [25]. Conversely,
simultaneous exposure of bone marrow-derived macro-sion in normal and nephritic rats. Glomerular macro-
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forming growth factor b. Crit Rev Eukaryot Gene Expr 9:33–44,phages to IFN-g abrogates the increased expression of
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